Victor E

No ORCID on file · 1 paper in corpus
2021
Frontiers in oncology ·doi:10.3389/fonc.2021.737943

The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior to chemoimmunotherapy regimens in patients with chron…